Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options

BACKGROUND: Being the standard-of-care for four decades, cisplatin-based chemotherapy is highly efficient in treating germ cell tumors (GCT). However, often refractory patients present with a remaining (resistant) yolk-sac tumor (YST(-R)) component, resulting in poor prognosis due to lack of novel t...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowron, Margaretha A., Kotthoff, Mara, Bremmer, Felix, Ruhnke, Katja, Parmaksiz, Fatma, Richter, Annika, Küffer, Stefan, Reuter-Jessen, Kirsten, Pauls, Stella, Stefanski, Anja, Ströbel, Philipp, Stühler, Kai, Nettersheim, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053054/
https://www.ncbi.nlm.nih.gov/pubmed/36991316
http://dx.doi.org/10.1186/s10020-023-00636-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053054/
https://www.ncbi.nlm.nih.gov/pubmed/36991316
http://dx.doi.org/10.1186/s10020-023-00636-3

Ejemplares similares